Compare OCUL & PGNY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | OCUL | PGNY |
|---|---|---|
| Founded | 2006 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Misc Health and Biotechnology Services |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.1B | 1.8B |
| IPO Year | 2014 | 2019 |
| Metric | OCUL | PGNY |
|---|---|---|
| Price | $9.17 | $23.13 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 9 | 10 |
| Target Price | $23.56 | ★ $26.50 |
| AVG Volume (30 Days) | ★ 2.7M | 1.5M |
| Earning Date | 05-05-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 14.04 |
| EPS | N/A | ★ 0.29 |
| Revenue | $1,990,000.00 | ★ $1,288,661,000.00 |
| Revenue This Year | $7.93 | $8.87 |
| Revenue Next Year | $96.07 | $9.76 |
| P/E Ratio | ★ N/A | $79.31 |
| Revenue Growth | 3.48 | ★ 10.40 |
| 52 Week Low | $6.23 | $16.10 |
| 52 Week High | $16.44 | $28.75 |
| Indicator | OCUL | PGNY |
|---|---|---|
| Relative Strength Index (RSI) | 48.17 | 70.73 |
| Support Level | $9.06 | $21.93 |
| Resistance Level | $9.93 | $24.06 |
| Average True Range (ATR) | 0.43 | 0.90 |
| MACD | -0.06 | 0.48 |
| Stochastic Oscillator | 23.67 | 81.48 |
Ocular Therapeutix Inc is a biotechnology company that specializes in therapies for diseases and conditions of the eye. The company uses its proprietary hydrogel platform technology to deliver therapeutic agents to the eye. Its pipeline consists of eye medication that aims to overcome the limitations of current eye-drop-based therapies for ophthalmic diseases and conditions. Its pipeline product includes Dextenza, OTX-TIC, OTX-TKI, and OTX-IVT.
Progyny Inc is a benefits management company specializing in fertility, family building, and women's health benefits solutions. Its clients include employers across various industries. The fertility benefits solution consists of treatment services (Smart Cycles), access to the Progyny network of high-quality fertility specialists that perform the Smart Cycle treatments, and active management of the selective network of high-quality provider clinics.